FINABLR-PLC
16.5.2019 18:33:06 CEST | Business Wire | Press release
London Stock Exchange welcomes Finablr PLC (“Finablr”), a global payments and foreign exchange company, to open London’s markets for trading and to celebrate the listing of the Company’s shares on the Premium Segment of the Main Market of LSE.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190516005902/en/
Finablr is a global platform for Payments and Foreign Exchange solutions underpinned by modern proprietary technology. With deep regulatory know-how, a relentless focus on innovation and leading industry partnerships, Finablr group companies provide a broad array of tailored and trusted financial solutions for consumers and businesses.
The Company is primed for growth as it benefits from structural drivers, like the globalisation of commerce driven by migration and mobility, cross-border trade, growth of e-commerce and the creation of connected communities. Through category-renowned brands, including UAE Exchange, Travelex, Xpress-Money, Unimoni, Remit2India, Ditto and Swych, Finablr sits at the centre of these intersecting trends, with an ability to serve both the end consumer and global corporates.
Finablr is present across the entire payments and foreign exchange value chain, from origination to processing to last-mile distribution. An integrated platform is at the heart of the Company’s proposition, supporting its omni-channel strategy with best-in-class operating capabilities and connectivity to global payment networks. This allows the Company to develop a deep understanding of its customers’ requirements and deliver a range of solutions tailored to their lifestyle and business needs.
In 2018, Finablr managed over 150,000,000 transactions, shifting the equivalent of $114.5 billion in volumes for its customers. It has a broad global reach spanning over 170 countries and has relationships with more than 100 regulators. The company’s truly global reach, its technology’s sophistication and its platform’s economies of scale have made Finablr a partner of choice for leading global banks, financial institutions, retailers, mobile wallet providers and payment and technology companies.
Dr. B R Shetty, Founder and Chairman of Finablr said: “Today marks a momentous milestone for Finablr and the beginning of an exciting new era to support the ever-evolving needs of a global customer. I would like to take this opportunity to thank our global patrons for their trust and faith in our commitment.”
Dr. Shetty, Finablr's largest shareholder and acknowledged by investors for star-studded track record of all-round value creation, had bought UK-based Travelex in 2015 $1.1 billion.
Finablr, as a group, has a global presence in over 170 countries and managed $114.5 billion in annual volumes in 2018. The group has been seeking to raise $200 from the IPO.
Promoth Manghat, Group Chief Executive Officer of Finablr said: “We are delighted that Finablr has joined the London Stock Exchange’s Premium Market, providing a new platform to grow over the coming years. We are very confident about the long-term prospects of the payments and foreign exchange solutions and the overarching presence of technology in such transactions and remain committed to generating the greatest value for our all our shareholders.”
Amidst unstable global macro and micro market situations bringing uncertainty in the broader socio-economic conditions, a rational price revision to 175 pence per share, down from an initially anticipated range above 200 pence, gave Finablr an implied market value of about $1.59 billion, said the bookrunner.
Books were covered at full value of the deal worth 192.5 million shares, thereby making the share offering to raise about £337 million. The deal size shall include a revised base deal size of 175 million shares and 17.5 million of over-allotment option shares.
The group claims to have built on the strength of their technology platform to provide best in class payments experiences to consumers and businesses. The group further claims that they are very well positioned to capture the future opportunities.
Dr. Shetty concluded , “ We have grown with a principle theme of Customer Service as our Currency and our endeavor would always be to serve the last person in the queue with equal zeal and care.”
Barclays, Goldman Sachs and J.P. Morgan Cazenove acted as Joint Global Co-ordinators and Joint Bookrunners, with EFG-Hermes, BofA Merrill Lynch and Numis also acting as Joint Bookrunners to the listing. Evercore acted as financial adviser to Finablr.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005902/en/
Contact:
Faiz Habib, +97123073333 Press.office@finablr.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
